Login
$VRCA
$3.20 -$0.36 (10.11%) Live

Company Executives

Officer Age In this role 2025 pay Source
Jayson Rieger Also a director
President and Chief Executive Officer
50 Not stated $741,403
John J. Kirby
Interim Chief Financial Officer
54 Since 2024
2 years
$614,600
David Zawitz
Chief Operating Officer, Chief Legal Officer and Secretary
45 Not stated Not reported
Noah Rosenberg
CMO
Title from the Form 4 dated Aug 17, 2026
59 Not stated $347,588

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
8
serving now
Independent
5 of 5
stated in the proxy; 3 not stated
Average tenure
5.8 years
from year joined
CEO also chairs the board
No
Paul B. Manning
Director Age On board Independent Other public boards 2025 pay Source
Paul B. Manning
70 2015
11 years
Not stated Candel Therapeutics, Inc., Liquidia Corporation Not stated
Jayson Rieger
50 2024
2 years
Not stated None stated Paid as CEO
Lawrence Eichenfield
68 2020
6 years
Independent None stated $69,339
Mark Prygocki
60 2018
8 years
Independent None stated $79,339
Charles Frantzreb
37 2025
1 year
Independent None stated Not stated
Sean Stalfort
56 2015
11 years
Not stated Acumen Pharmaceuticals, Inc., Taysha Gene Therapies, Inc. Not stated
Diem Nguyen
54 2020
6 years
Independent SIGA Technologies, Candel Therapeutics, Inc. $55,589
Gavin Corcoran
63 2025
1 year
Independent None stated $45,315

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

7 disclosed in the proxy filed Apr 20, 2026
Paul B. Manning
chairman of our Board of Directors
Approximately $17.5 million

Purchased shares of common stock and Series C Warrants in the Private Placement through affiliated entities.

Jayson Rieger
Chief Executive Officer
Approximately $400,000

Purchased shares of common stock and Series C Warrants in the Private Placement.

John J. Kirby
interim Chief Financial Officer
Approximately $15,000

Purchased shares of common stock and Series C Warrants in the Private Placement.

David Zawitz
Chief Operating Officer, Chief Legal Officer and Secretary
Approximately $42,000

Purchased shares of common stock and Series C Warrants in the Private Placement.

Noah Rosenberg
Chief Medical Officer
Approximately $10,000

Purchased shares of common stock and Series C Warrants in the Private Placement.

Charles Frantzreb
Class I director designated by Caligan Partners LP and its affiliates
Amount not stated

Appointed as a Class I director designated by Caligan in connection with the Private Placement, with a continuing board designation right for Caligan.

With Caligan Partners LP and its affiliates Open in proxy
Clinical Enrollment LLC
controlled by Bryan Manning, the son of Paul B. Manning
$90,000
year ended December 31, 2024

Clinical service agreement under which Clinical Enrollment provides recruiting support services for the VP-315 clinical trial.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support